Terns Pharmaceuticals, Inc. entered a merger agreement with Merck on March 24, 2026, offering shareholders $53.00 per share. This event could significantly change the company's structure and is noteworthy for investors.
AI Assistant
TERNS PHARMACEUTICALS INC
2026
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.